Cenovus Energy (CVE) Gets Macquarie Lower Rating, Redmile Group Lifted Puma Biotechnology (PBYI) Stake

June 21, 2017 - By Henry Gaston

Redmile Group Llc increased Puma Biotechnology Inc (PBYI) stake by 94.8% reported in 2016Q4 SEC filing. Redmile Group Llc acquired 627,854 shares as Puma Biotechnology Inc (PBYI)’s stock declined 6.09%. The Redmile Group Llc holds 1.29 million shares with $39.61M value, up from 662,286 last quarter. Puma Biotechnology Inc now has $2.93 billion valuation. The stock rose 3.50% or $2.75 reaching $81.25 per share. About 579,688 shares traded. Puma Biotechnology Inc (NYSE:PBYI) has risen 23.65% since June 21, 2016 and is uptrending. It has outperformed by 6.95% the S&P500.

Among 14 analysts covering Cenovus Energy Inc (NYSE:CVE), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Cenovus Energy Inc has $27 highest and $18 lowest target. $22.43’s average target is 215.47% above currents $7.11 stock price. Cenovus Energy Inc had 19 analyst reports since July 21, 2015 according to SRatingsIntel. JP Morgan maintained it with “Neutral” rating and $18 target in Tuesday, December 15 report. Morgan Stanley upgraded Cenovus Energy Inc (USA) (NYSE:CVE) on Monday, June 13 to “Overweight” rating. The stock of Cenovus Energy Inc (USA) (NYSE:CVE) earned “Neutral” rating by Nomura on Thursday, January 21. The company was reinitiated on Friday, May 26 by Credit Suisse. The firm has “Outperform” rating given on Thursday, April 28 by RBC Capital Markets. Goldman Sachs upgraded the shares of CVE in report on Friday, March 11 to “Conviction Buy” rating. The stock has “Neutral” rating by UBS on Tuesday, January 26. The firm has “Neutral” rating by Bank of America given on Friday, August 19. The firm has “Underperform” rating given on Tuesday, January 24 by Macquarie Research. As per Tuesday, January 26, the company rating was upgraded by Goldman Sachs.

Among 8 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Puma Biotechnology Inc had 22 analyst reports since August 27, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Credit Suisse on Wednesday, April 19. The rating was downgraded by RBC Capital Markets on Tuesday, March 29 to “Sector Perform”. Citigroup upgraded the stock to “Buy” rating in Monday, December 14 report. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Outperform”. As per Monday, April 11, the company rating was maintained by UBS. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, September 21. The rating was maintained by JP Morgan with “Overweight” on Tuesday, March 29. The stock of Puma Biotechnology Inc (NASDAQ:PBYI) has “Buy” rating given on Tuesday, May 23 by Stifel Nicolaus. Credit Suisse maintained Puma Biotechnology Inc (NASDAQ:PBYI) rating on Tuesday, March 29. Credit Suisse has “Outperform” rating and $50 target. Citigroup initiated the shares of PBYI in report on Thursday, September 3 with “Neutral” rating.

Investors sentiment decreased to 1.32 in Q4 2016. Its down 0.17, from 1.49 in 2016Q3. It turned negative, as 36 investors sold PBYI shares while 21 reduced holdings. 22 funds opened positions while 53 raised stakes. 34.24 million shares or 16.48% more from 29.40 million shares in 2016Q3 were reported. 1.29M were reported by Redmile Group Lc. Tourbillon Cap Partners Lp invested 0.26% of its portfolio in Puma Biotechnology Inc (NASDAQ:PBYI). New York State Common Retirement Fund reported 26,600 shares stake. Creative Planning stated it has 1,638 shares or 0% of all its holdings. Kessler Grp Lc has invested 0.73% in Puma Biotechnology Inc (NASDAQ:PBYI). Adirondack Tru owns 0% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 30 shares. Sivik Global Healthcare Limited Liability holds 0.44% or 30,000 shares. Moreover, Sabby Management Ltd Liability Co has 0.18% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 103,243 shares. Highbridge Cap Management Limited Liability Corp invested 0.04% of its portfolio in Puma Biotechnology Inc (NASDAQ:PBYI). Grp holds 14,198 shares or 0% of its portfolio. Cam Hldgs A S has 0.02% invested in Puma Biotechnology Inc (NASDAQ:PBYI) for 30,000 shares. Blackrock Advsrs Lc invested in 67,799 shares or 0% of the stock. Schwab Charles Invest Mgmt holds 113,174 shares or 0% of its portfolio. Orbimed Advsrs Ltd reported 0.89% in Puma Biotechnology Inc (NASDAQ:PBYI). Perceptive Advsr Ltd Llc accumulated 0.02% or 7,344 shares.

Since January 20, 2017, it had 0 insider purchases, and 9 sales for $158.24 million activity. The insider ADAGE CAPITAL PARTNERS GP – L.L.C. sold 507,128 shares worth $44.54 million. Shares for $76,208 were sold by BRYCE RICHARD PAUL. $76,208 worth of Puma Biotechnology Inc (NASDAQ:PBYI) was sold by CHARNAS ROBERT on Friday, January 20. Another trade for 10,202 shares valued at $339,064 was sold by AUERBACH ALAN H. Lo Steven sold $76,108 worth of stock. On Friday, January 20 the insider EYLER CHARLES R sold $27,253.

Redmile Group Llc decreased Array Biopharma Inc (NASDAQ:ARRY) stake by 39,296 shares to 16.62M valued at $146.08M in 2016Q4. It also reduced Model N Inc (NYSE:MODN) stake by 741,045 shares and now owns 809,914 shares. Boston Scientific Corp (NYSE:BSX) was reduced too.

Cenovus Energy Inc. is a Canada-based integrated oil company. The company has market cap of $7.98 billion. The Firm is engaged in the business of developing, producing and marketing crude oil, natural gas liquids and natural gas. It currently has negative earnings. The Company’s divisions include Oil Sands, Conventional, Refining and Marketing, and Corporate and Eliminations.

Analysts await Cenovus Energy Inc (USA) (NYSE:CVE) to report earnings on July, 27. They expect $0.04 earnings per share, up 200.00% or $0.08 from last year’s $-0.04 per share. CVE’s profit will be $44.89 million for 44.44 P/E if the $0.04 EPS becomes a reality. After $-0.04 actual earnings per share reported by Cenovus Energy Inc (USA) for the previous quarter, Wall Street now forecasts -200.00% EPS growth.